Progressive Familial Intrahepatic Cholestasis (PFIC) Archives

FDA Approves First Drug Treatment for Patients With PFIC

Approvals, AstraZeneca, Clinical Trials, European Medicines Agency, FDA, Progressive Familial Intrahepatic Cholestasis (PFIC), Pruritus (Severe Itching), R&D, Therapeutics

Albireo Pharma, a spinout of AstraZeneca, won regulatory approval for the first drug aimed at pruritus in patients with all subtypes of progressive familial intrahepatic cholestasis (PFIC).

July 21, 2021/by BioSpace

FDA Accepts NDA Filing for Albireo’s Pediatric PFIC Drug

Accepted NDA, AstraZeneca, Clinical Trials, FDA, New Drug Applications, PDUFA, Pediatric, Priority Review Status, Progressive Familial Intrahepatic Cholestasis (PFIC), Pruritus (Severe Itching), R&D, Spin-Outs

AstraZeneca spinout Albireo Pharma is moving closer to securing regulatory approval for the company’s treatment of pruritus in patients with progressive familial intrahepatic cholestasis (PFIC).

January 25, 2021/by Andrew Humphreys